Through the strategic acquisition, management, and application of patents, GWOXI ensures that its unique technologies and products are fully protected. This approach helps to prevent potential infringement risks and consolidate the company's market position.
As of July 23, 2025, the company has obtained a total of 120 patents.
East Asia
101 patents (Taiwan, China, Japan)
Southeast Asia
5 patents (Vietnam, Indonesia, Singapore, Malaysia)
Europe and America
14 patents (United States)
East Asia
Southeast Asia
Europe and America
GWOXI's Nigiro-Med® technology platform is designed to screen for optimal stem cell culture conditions (optimal microenvironment), direct stem cell differentiation, and induce stem cells to produce therapeutic functions (induction).The raw materials for these active ingredients are then processed using the company's proprietary Micttake® technology platform to separate, extract, purify, and transform them into effective ultra-micro molecules. This process allows us to create our unique proprietary conditioned medium and a special stem cell activation process, with the aim of developing distinct stem cell new drugs for various diseases.
1. Simulating the in vivo microenvironment
( Mimicking the Microenvironment )
2. Develop a special process
( Developing Proprietary Technologies )
3. From Raw Materials to Preparations
( Transforming Naive Stem Cell into Stem Cell Medicine)
The dual regenerative platforms, Nigiro-Med® and Micttake®, rapidly screen and combine effective conditioned media. By incorporating a special process, they accelerate GWOXI's stem cell new drug development.
Press Releases
Press Releases-
04202507Press ReleasesGWOXI Stem Cell Enters Japan to Expand International Regenerative Medicine Business, Pushing to Internationalize Adipose Stem Ce -
16202506Press ReleasesGWOXI Stem Cell Makes a Preemptive Strategic Move to Address the Dual Challenges of Population Aging and Younger-Onset Stroke. -
13202505Press ReleasesGWOXI's New Stem Cell Drug for Osteoarthritis Approved to Start a Phase III Clinical Trial in Taiwan.